UNASSIGNED: Balancing immunosuppression after liver transplant is difficult, with clinical events common. We investigate whether a novel immune biomarker based on a laboratory platform with widespread availability that measures interferon gamma (IFNy) after stimulation with a lyophilized ball containing an adaptive and innate immune stimulant can predict events following transplantation. 75 adult transplant recipients were prospectively monitored in a blinded, observational study. 55/75 (73.3%) @entity1 experienced a total 89 clinical events. Most events occurred within the first month. Low week 1 (W1) results were significantly associated with risk of @entity281 (AUROC 0.74, p=0.008). IFNy<= 1.30IU/mL (LR+ 1.93, sensitivity 71.4%, specificity 63.0%) was associated with the highest risk for @entity281 with minimal rejection risk. Nearly half the cohort (27/60, 45.0%) expressed IFNy<= 1.30IU/mL. Moreover, an elevated W1 result was significantly associated with the risk of rejection within the first month post-transplant (AUROC 0.77, p=0.002), but no episodes of @entity281 . On multivariate logistic regression, IFNy>= 4.49IU/mL (OR 4.75) may be an independent predictor of rejection (p=0.05). CONCLUSION: Low IFNy suggesting over-suppression is associated with @entity281 , while high IFNy indicating under-suppression is associated with rejection. This assay offers the potential to allow individualisation and optimisation of immunosuppression that could fundamentally alter the way @entity1 are managed following transplantation. This article is protected by copyright. All rights reserved.

A novel immune function biomarker identifies XXXX at risk of clinical events early following liver transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections', 'early infection', 'infection']
@entity1 :: (9606,Species) :: ['patients']
